SCHEMBL2677286

SCHEMBL2677286

O=C(O)N1CCCN(C(=O)CC2CCCO2)CC1

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.55
KDM4E B2RXH2 4/20 0.55
LMNA P02545 1/20 0.55
L3MBTL1 Q9Y468 2/20 0.42
USP2 O75604 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
GAA P10253 1/20 0.39
HPGD P15428 2/20 0.39
TP53 P04637 1/20 0.39
ALOX12 P18054 1/20 0.39
NAMPT P43490 1/20 0.39
KMT2A Q03164 3/20 0.38
MEN1 O00255 2/20 0.38
ATM Q13315 1/20 0.38
CYP3A4 P08684 1/20 0.37
CYP2C19 P33261 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4629989 0.79 KDM4E (0.49) ALDH1A1KDM4ELMNAL3MBTL1USP2
SCHEMBL27564776 0.78 ALDH1A1 (0.48) ALDH1A1KDM4ELMNAUSP2SMN1; SMN2
SCHEMBL2676512 0.76 MEN1 (0.42) ALDH1A1KDM4ELMNAL3MBTL1TP53
SCHEMBL15014609 0.76 ALDH1A1 (0.56) ALDH1A1KDM4ELMNAL3MBTL1SMN1; SMN2
SCHEMBL22875137 0.76 KDM4E (0.46) ALDH1A1KDM4ELMNAL3MBTL1SMN1; SMN2
SCHEMBL2676443 0.75 CNR2 (0.49) ALDH1A1KDM4ETP53NAMPTATM
SCHEMBL12424283 0.74 ALDH1A1 (0.47) ALDH1A1KDM4ELMNAL3MBTL1HPGD
SCHEMBL2678553 0.73 KDM4E (0.49) ALDH1A1KDM4ETP53NAMPTKMT2A
SCHEMBL12384811 0.73 ALDH1A1 (0.46) ALDH1A1KDM4ELMNAL3MBTL1SMN1; SMN2
SCHEMBL2677323 0.72 RECQL (0.59) ALDH1A1KDM4ESMN1; SMN2KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173638-B2 Compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-05-08 US claimed
US-20100009964-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-01-14 US claimed
WO-2008064054-A2 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-05-29 WO claimed
US-8173638-B2 Compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-05-08 US disclosed
US-20100009964-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-01-14 US disclosed
WO-2008064054-A2 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-05-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100009964-A1 Compounds Which Modulate The CB2 Receptor CNR2, CNR1, OPRL1 ALDH1A1 1695/4885KDM4E 3926/4885LMNA 4379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.